Omnaris

Asthma, Bronchoconstriction, Chronic Obstructive Pulmonary Disease + 2 more
Treatment
20 Active Studies for Omnaris

What is Omnaris

CiclesonideThe Generic name of this drug
Treatment SummaryCiclesonide, brand name Alvesco, is a steroid used to treat breathing problems caused by obstructive airway diseases.
Omnarisis the brand name
image of different drug pills on a surface
Omnaris Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Omnaris
Ciclesonide
2008
15

Effectiveness

How Omnaris Affects PatientsCiclesonide works by being broken down into a metabolite (des-ciclesonide) once it is inhaled. Des-ciclesonide has anti-inflammatory properties and is very strong compared to ciclesonide itself. It is not fully understood how ciclesonide works to treat allergic rhinitis, but it is believed to work by affecting cells and substances (like histamine and cytokines) that are involved in inflammation.
How Omnaris works in the bodyCiclesonide works by reducing inflammation in the body. It does this by targeting cells that cause inflammation and restricting their movement and activity. It also reduces the production of substances that create swelling and pain. Ciclesonide works by activating certain receptors in cells, which causes changes in the expression of certain genes that control the inflammatory response. This includes suppressing the expression of the gene that produces interleukin 2, a substance that causes inflammation.

When to interrupt dosage

The prescribed amount of Omnaris depends upon the diagnosed affliction, such as Perennial Allergic Rhinitis (PAR), Hay Fever and Bronchoconstriction. The measure of dosage is contingent upon the method of delivery (e.g. Aerosol, metered - Respiratory (inhalation) or Aerosol, metered) featured in the table beneath.
Condition
Dosage
Administration
Asthma
0.05 mg, , 0.08 mg, 0.16 mg, 0.037 mg, 0.05 mg/pump actuation, 0.1 mg/pump actuation, 0.2 mg/pump actuation
, Nasal, Spray - Nasal, Spray, Aerosol, metered - Respiratory (inhalation), Aerosol, metered, Respiratory (inhalation), Aerosol, metered - Nasal, Spray, metered - Nasal, Spray, metered
Bronchoconstriction
0.05 mg, , 0.08 mg, 0.16 mg, 0.037 mg, 0.05 mg/pump actuation, 0.1 mg/pump actuation, 0.2 mg/pump actuation
, Nasal, Spray - Nasal, Spray, Aerosol, metered - Respiratory (inhalation), Aerosol, metered, Respiratory (inhalation), Aerosol, metered - Nasal, Spray, metered - Nasal, Spray, metered
Chronic Obstructive Pulmonary Disease
0.05 mg, , 0.08 mg, 0.16 mg, 0.037 mg, 0.05 mg/pump actuation, 0.1 mg/pump actuation, 0.2 mg/pump actuation
, Nasal, Spray - Nasal, Spray, Aerosol, metered - Respiratory (inhalation), Aerosol, metered, Respiratory (inhalation), Aerosol, metered - Nasal, Spray, metered - Nasal, Spray, metered
Hay Fever
0.05 mg, , 0.08 mg, 0.16 mg, 0.037 mg, 0.05 mg/pump actuation, 0.1 mg/pump actuation, 0.2 mg/pump actuation
, Nasal, Spray - Nasal, Spray, Aerosol, metered - Respiratory (inhalation), Aerosol, metered, Respiratory (inhalation), Aerosol, metered - Nasal, Spray, metered - Nasal, Spray, metered
Rhinitis, Allergic
0.05 mg, , 0.08 mg, 0.16 mg, 0.037 mg, 0.05 mg/pump actuation, 0.1 mg/pump actuation, 0.2 mg/pump actuation
, Nasal, Spray - Nasal, Spray, Aerosol, metered - Respiratory (inhalation), Aerosol, metered, Respiratory (inhalation), Aerosol, metered - Nasal, Spray, metered - Nasal, Spray, metered

Warnings

Omnaris has one contraindication and should not be taken while having any of the conditions listed in the following table.Omnaris Contraindications
Condition
Risk Level
Notes
Status Asthmaticus
Do Not Combine
There are 20 known major drug interactions with Omnaris.
Common Omnaris Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Ciclesonide is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Ciclesonide is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abetimus
Major
The risk or severity of adverse effects can be increased when Ciclesonide is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Ciclesonide is combined with Acteoside.
Aldesleukin
Major
The therapeutic efficacy of Aldesleukin can be decreased when used in combination with Ciclesonide.
image of a doctor in a lab doing drug, clinical research

Omnaris Novel Uses: Which Conditions Have a Clinical Trial Featuring Omnaris?

245 active trials are currently being conducted to assess the suitability of Omnaris in alleviating Chronic Obstructive Pulmonary Disease (COPD), Asthma and Perennial Allergic Rhinitis (PAR).
Condition
Clinical Trials
Trial Phases
Asthma
92 Actively Recruiting
Phase 1, Phase 4, Early Phase 1, Phase 2, Not Applicable, Phase 3
Hay Fever
0 Actively Recruiting
Rhinitis, Allergic
0 Actively Recruiting
Bronchoconstriction
0 Actively Recruiting
Chronic Obstructive Pulmonary Disease
77 Actively Recruiting
Phase 3, Phase 1, Phase 2, Not Applicable, Early Phase 1, Phase 4

Omnaris Reviews: What are patients saying about Omnaris?

5Patient Review
10/27/2016
Omnaris for Inflammation of the Nose due to an Allergy
This is the best. Flonase and Nasonex have decongestants built in, which often leads to side effects like anxiety or sleep issues. This doesn't have that problem!
5Patient Review
9/30/2020
Omnaris for Seasonal Runny Nose
This treatment is really effective for me in reducing ragweed allergies. I've been using it for over five years now and it makes a big difference during the high-pollen months.
4.7Patient Review
10/19/2018
Omnaris for Inflammation of the Nose due to an Allergy
I have to switch to a different nasal spray when my seasons are done because Omnaris gives me horrific headaches - dries me up too much during the fall/winter months. But it's extremely effective for spring/summer.
4.7Patient Review
9/27/2014
Omnaris for Non-Seasonal Allergic Runny Nose
I'm a new user, and this nose spray has been a lifesaver. I've tried seven different scripts ( all for different medications) and none of them have worked as well as this one. Thank you!
4.3Patient Review
5/28/2012
Omnaris for Inflammation of the Nose due to an Allergy
3.7Patient Review
4/23/2013
Omnaris for Inflammation of the Nose due to an Allergy
Though this was the first medicated nasal spray I tried, it proved effective against my allergy symptoms. However, it comes with THE WORST headache I've ever had to endure. It's so bad that neck movement is impossible and Advil does nothing to alleviate the pain. Additionally, it seems to have thrown off my birth control pill cycle.
3.7Patient Review
6/7/2014
Omnaris for Inflammation of the Nose due to an Allergy
This has helped me a lot, but I'm still experiencing some symptoms.
3.7Patient Review
8/2/2012
Omnaris for Non-Seasonal Allergic Runny Nose
I had a terrible reaction to this medication and had to stop taking it after only a few days. I couldn't breathe, my tongue felt swollen, my lips were numb, and I felt extremely thirsty.
2.3Patient Review
1/26/2014
Omnaris for Inflammation of the Nose due to an Allergy
This was the only treatment that worked for me, but it's quite expensive and not covered by insurance.
1.7Patient Review
5/27/2012
Omnaris for Seasonal Runny Nose
1.7Patient Review
5/31/2018
Omnaris for Inflammation of the Nose due to an Allergy
I used this treatment for three months and saw no results.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about omnaris

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How effective is Omnaris?

"Based on the 16 ratings for Omnaris, the average rating is 6.1 out of 10. 44% of reviewers had a positive experience, while 31% had a negative experience."

Answered by AI

What is difference between Flonase and Omnaris?

"Ciclesonide, sold under the brand name Omnaris, is a nasal spray medication used to treat allergy symptoms. It is available over-the-counter and is cheaper than many of its alternatives. Fluticasone, sold under the brand name Flonase, is a nasal spray medication used to treat allergy symptoms. It has very little to no side effects since it is a nasal spray and doesn't expose the rest of your body to the medicine."

Answered by AI

What are the side effects of Omnaris?

"headache, dizziness; nosebleed, irritation of the nose; a blocked nose, sore throat; or earache."

Answered by AI

What is Omnaris used for?

"This medication is used to treat symptoms of the nose (stuffiness or congestion, runny nose, itching, and sneezing) caused by seasonal and year-round nasal allergies. Ciclesonide works by reducing the inflammation of the nasal passages."

Answered by AI

Clinical Trials for Omnaris

Image of Stanford University in Stanford, United States.

MoblO2 for Chronic Lung Diseases

18+
All Sexes
Stanford, CA
Many patients with chronic lung disease (e.g., chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD)) require supplemental oxygen (O2) at some point during their disease course. Practitioners prescribe O2 to patients with chronic lung disease in hopes of the following: 1) that it will limit desaturation events and combat breathlessness, thus preventing the frustratingly slow pace and numerous rest breaks patients are forced to adopt while doing even simple tasks; 2) that it will allow patients to be more active physically (perhaps increase their ability to exercise) and socially (perhaps leave the home more often); 3) that it will stave off putative complications of hypoxemia (e.g., cognitive dysfunction, pulmonary hypertension) and 4) that it will improve health-related quality of life (HRQL). However, despite the rationale for O2, and prescribers' good intentions, patients generally view O2 with frustration and fear - it threatens their HRQL, which is already impaired by having a condition that imposes itself on every aspect of their lives. Nasal cannulas and delivery devices call unwanted attention to patients when they are out in public. O2 users feel stigmatized and are often viewed as "smokers who get what they deserve, even if they never smoked a day in their lives" - or as disabled, sick or even infectious. O2 steals patients' independence, forcing them to plan their lives around it. The anxiety that patients and their caregivers experience around running out of oxygen, or not getting enough, immobilizes them and restricts participation in activities outside of the home. O2 disrupts the home environment, adding stress, and creating a burden for patients' caregiver-loved-ones who are often saddled with the responsibility of ensuring adequate equipment and supply of O2, and O2 is a constant reminder to patients they are living with a condition that could shorten their lives. O2 delivery equipment is typically heavy, unwieldy and intimidating. Different recommendations (e.g., insurance companies use 88% as a cut-off for SpO2, while many practitioners focus on 90%) make it confusing for patients, which almost certainly affects adherence. O2-requiringpatients are starving for things that can make their lives easier. An auto-adjusting O2 delivery device - one that automatically delivers the correct amount of O2 to maintain blood oxygen at desired, pre-set levels - would alleviate the need for patients to constantly (incessantly for many) monitor their peripheral oxygen saturation (SpO2) and adjust O2flow to meet the demands as exertion levels vary . The MoblO2 device is a battery-operated, light-weight, closed-loop O2 delivery device that houses a regulator (which attaches to compressed gas O2 tanks) and adjusts O2 flow to meet a pre-set blood oxygen level. A pulse oximeter is worn on the ear and transmits via Bluetooth to the device, which adjusts an internal valve to control flow on a second-to-second basis. The user sets the dial to the highest flow of O2 needed to meet the demands of activities they might perform (up to 15 liters per minute), and the device adjusts flow, up to the pre-set level to maintain SpO2 at a preset level (e.g., \> 90%). To conserve O2 supply in the tank - and to avoid over-oxygenation (which could be problematic for a small percentage of patients with the most severe COPD) - the MoblO2 begins to limit O2 flow at a SpO2 of 93%. The device can be manually over-ridden by the user, and should the battery run out - or the device fail for some unforeseen reason - the default position is valve open, so the users receive whatever flow of oxygen has been set on the dial. Given the substantial burdens of O2 on patients and their families, the hassles patients describe with having to monitor their SpO2 and repeatedly adjust the flow of O2 to meet their needs, patients and experts around the world have called for improvements in O2 delivery equipment. The MoblO2 is just such a remarkable improvement and a giant step forward in helping to ease the burdens of O2 on patients who require it. The purpose of this study is to investigate the effects of the MoblO2 O2 delivery device on a range of outcomes, including physical activity, amount (liters) O2 use; maintenance of adequate SpO2 levels; patient reported outcomes including symptoms, HRQL and satisfaction with the MoblO2 O2 device.
Waitlist Available
Has No Placebo
Stanford UniversityJeff Swigris, DO, MSMinnesota Health Solutions
Have you considered Omnaris clinical trials? We made a collection of clinical trials featuring Omnaris, we think they might fit your search criteria.Go to Trials
Image of The University of Tennessee Graduate School of Medicine in Knoxville, United States.

Nebulizer vs Inhaler for COPD

18+
All Sexes
Knoxville, TN
The purpose of this study is to compare the effectiveness of inhaled bronchodilators delivered via nebulizers vs. dry powder inhalers (DPIs) in symptomatic participants with Chronic Obstructive Pulmonary Disease (COPD) who have airflow obstruction (FEV1/FVC ≤ 70%) and show significant air trapping (RV ≥ 120% of predicted). The investigators hypothesize that, in patients with symptomatic COPD, therapy with a long-acting anti muscarinic agent/long-acting beta agonist (LAMA/LABA) combination administered by nebulizer will improve hyperinflation (increase in inspiratory capacity and reduction in residual volume) and reduce symptoms related to COPD to a greater extent than LAMA/LABA therapy given by a DPI. The study aims to demonstrate the following: 1. Compare the values of inspiratory capacity (IC) and residual volume (RV) in patients receiving LAMA/LABA by DPI with those receiving LAMA/LABA by nebulizer 2. Compare patient reported outcomes (COPD Assessment Test (CAT score), Baseline/Transition Dyspnea Index (BDI/TDI) and the St. George Respiratory Questionnaire (SGRQ) in symptomatic patients with COPD receiving LAMA/LABA by DPI with those receiving LAMA/LABA by nebulizer
Phase 4
Recruiting
The University of Tennessee Graduate School of MedicineTheravance Biopharma
Have you considered Omnaris clinical trials? We made a collection of clinical trials featuring Omnaris, we think they might fit your search criteria.Go to Trials
Have you considered Omnaris clinical trials? We made a collection of clinical trials featuring Omnaris, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security